Expression of macrophage inhibitory cytokine‐1 in prostate cancer bone metastases induces osteoclast activation and weight loss

Macrophage inhibitory cytokine‐1 (MIC‐1) belongs to the bone morphogenic protein/transforming growth factor‐β (BMP/TGF‐β) superfamily. Serum MIC‐1 concentrations are elevated in patients with advanced prostate cancer. The effects of MIC‐1 on prostate cancer bone metastases are unknown.

[1]  A. Bjartell,et al.  FGF‐8 is involved in bone metastasis of prostate cancer , 2008, International journal of cancer.

[2]  W. D. Fairlie,et al.  Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1 , 2007, Nature Medicine.

[3]  P. Lehenkari,et al.  Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. , 2007, European journal of pharmacology.

[4]  K. Selander,et al.  Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro , 2007, The Prostate.

[5]  P. Tak,et al.  Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. , 2007, Arthritis and rheumatism.

[6]  A. Jukkola-Vuorinen,et al.  Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases , 2007, Cancer Epidemiology Biomarkers & Prevention.

[7]  G. Schett.  Cells of the synovium in rheumatoid arthritis. Osteoclasts , 2007, Arthritis research & therapy.

[8]  S. Baek,et al.  NSAID activated gene (NAG-1), a modulator of tumorigenesis. , 2006, Journal of biochemistry and molecular biology.

[9]  M. Lucia,et al.  Prostate derived factor in human prostate cancer cells: Gene induction by vitamin D via a p53‐dependent mechanism and inhibition of prostate cancer cell growth , 2006, Journal of cellular physiology.

[10]  A. Monks,et al.  Drug-Induced Expression of Nonsteroidal Anti-Inflammatory Drug-Activated Gene/Macrophage Inhibitory Cytokine-1/Prostate-Derived Factor, a Putative Tumor Suppressor, Inhibits Tumor Growth , 2006, Journal of Pharmacology and Experimental Therapeutics.

[11]  Rebecca L. Jones,et al.  TGF-β superfamily expression and actions in the endometrium and placenta , 2006 .

[12]  P. Härkönen,et al.  Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. , 2006, Endocrinology.

[13]  Stefan Bauer,et al.  Endosomal Translocation of Vertebrate DNA Activates Dendritic Cells via TLR9-Dependent and -Independent Pathways 1 , 2005, The Journal of Immunology.

[14]  S. Badve,et al.  The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. , 2005, Carcinogenesis.

[15]  J. Kench,et al.  The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. , 2005, Cancer research.

[16]  P. Jiang,et al.  Monitoring of skeletal progression of prostate cancer by GFP imaging, X‐ray, and serum OPG and PTHrP , 2005, The Prostate.

[17]  J. Risteli,et al.  Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. , 2005, European journal of endocrinology.

[18]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[19]  Jae-Geun Yoon,et al.  Myeloid Differentiation Factor 88-dependent Post-transcriptional Regulation of Cyclooxygenase-2 Expression by CpG DNA , 2003, Journal of Biological Chemistry.

[20]  C. Suarez‐Cuervo,et al.  Bisphosphonate Induced Growth Inhibition of Breast Cancer Cells is Augmented by p38 Inhibition , 2003, Breast Cancer Research and Treatment.

[21]  L. Vassilev,et al.  Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. , 2003, Molecular cancer therapeutics.

[22]  J. Zaunders,et al.  Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. , 2003, Cancer research.

[23]  K. Song,et al.  Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. , 2003, Cancer research.

[24]  K. Kinzler,et al.  MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  K. Iczkowski,et al.  Overexpression of NSAID-Activated Gene Product in Prostate Cancer , 2003, International journal of surgical pathology.

[26]  S. Batra,et al.  Dysregulated expression of MIC-1/PDF in human prostate tumor cells. , 2003, Biochemical and biophysical research communications.

[27]  J. Welsh,et al.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Akira,et al.  Recognition of pathogen-associated molecular patterns by TLR family. , 2003, Immunology letters.

[29]  A. Multani,et al.  Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model. , 2002, The Journal of urology.

[30]  Erwin G. Van Meir,et al.  Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1 , 2002, Oncogene.

[31]  Angie Rizzino,et al.  Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. , 2002, Carcinogenesis.

[32]  N. Takahashi,et al.  Regulatory mechanisms of osteoblast and osteoclast differentiation. , 2002, Oral diseases.

[33]  G. Risbridger,et al.  An in vivo model of prostate carcinoma growth and invasion in bone , 2002, Cell and Tissue Research.

[34]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[35]  R. Vessella,et al.  Placental bone morphogenetic protein (PLAB) gene expression in normal, pre‐malignant and malignant human prostate: Relation to tumor development and progression , 2001, International journal of cancer.

[36]  S. Baek,et al.  Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. , 2001, Molecular pharmacology.

[37]  W. D. Fairlie,et al.  The Propeptide of the Transforming Growth Factor-β Superfamily Member, Macrophage Inhibitory Cytokine-1 (MIC-1), Is a Multifunctional Domain That Can Facilitate Protein Folding and Secretion* , 2001, The Journal of Biological Chemistry.

[38]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[39]  W. D. Fairlie,et al.  The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. , 2000, The Journal of clinical endocrinology and metabolism.

[40]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[41]  C. Arrowsmith,et al.  Placental Transforming Growth Factor-β Is a Downstream Mediator of the Growth Arrest and Apoptotic Response of Tumor Cells to DNA Damage and p53 Overexpression* , 2000, The Journal of Biological Chemistry.

[42]  S. Breit,et al.  The propeptide of macrophage inhibitory cytokine (MIC‐1), a TGF‐β superfamily member, acts as a quality control determinant for correctly folded MIC‐1 , 2000, The EMBO journal.

[43]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[44]  W. D. Fairlie,et al.  MIC‐1 is a novel TGF‐β superfamily cytokine associated with macrophage activation , 1999, Journal of leukocyte biology.

[45]  S. Reddy,et al.  Immortalization of osteoclast precursors by targeting Bcl -XL and Simian virus 40 large T antigen to the osteoclast lineage in transgenic mice. , 1998, The Journal of clinical investigation.

[46]  S. Vukicevic,et al.  Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.

[47]  W. D. Fairlie,et al.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Kanis,et al.  Bone and cancer: pathophysiology and treatment of metastases. , 1995, Bone.

[49]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[50]  Väänänen Hk.  Mechanism of bone turnover. , 1993 .

[51]  Y. Amagai,et al.  In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria , 1983, The Journal of cell biology.

[52]  Claudia Mauri,et al.  Cells of the synovium in rheumatoid arthritis , 2007 .

[53]  Rebecca L. Jones,et al.  TGF-beta superfamily expression and actions in the endometrium and placenta. , 2006, Reproduction.

[54]  K. Pienta,et al.  Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone , 2004, Cancer and Metastasis Reviews.

[55]  H. Väänänen.  Mechanism of bone turnover. , 1993, Annals of medicine.